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Several neurodegenerative disorders, including Parkinson’s and Alzheimer’s diseases, are charac-
terized neuropathologically by accumulation of misfolded proteins such as a-synuclein that disrupts
scaffold molecules in the caveolae. A new study by Ihara et al. in this issue of Neuron shows that
a novel scaffold protein, Sept4, may be an important player in modulating the pathological alterations
of a-synuclein in models of Parkinson’s disease, suggesting that gene therapies targeting scaffold
proteins might be effective in the treatment of neurodegenerative disorders.Neurodegenerative disorders such as
Parkinson’s (PD) and Alzheimer’s (AD)
diseases are a significant and grow-
ing concern to the population. During
the aging process, abnormal accumu-
lation and misfolding of a-synuclein
(SYN) and amyloid-b protein (Ab) in se-
lected neuronal groups leads to a wide
spectrum of neurological disorders
with cognitive dysfunction, parkinson-
ism, and autonomic dysfunction. To-
gether, these disorders account for
the great majority of the cases with
combined movement disorders and
dementia in the US. Therefore, better
understanding the pathogenesis of
these disorders and developing new
therapies is a major priority.
Ihara et al. in this issue of Neuron
report that Sept4, a novel scaffold pro-
tein, is reduced in the caudo-putamen
region of patients with PD. Moreover,
the authors found that Sept4 plays an
important role in facilitating dopami-
nergic transmission at the synapse
terminals of the striato-nigral pathway
(Ihara et al., 2007) and also appears
to have a role in modulating the patho-
logical alterations associated with the
accumulation of oligomerized phos-
phorylated SYN in a transgenic mouse
model of PD.
Septin proteins were first isolated
in yeast as components of the septin
ring responsible for the budding of
the daughter cell from the mother cell
in cell division. All septins are GTP-
binding proteins that appear to act inscaffold functions (Longtine and Bi,
2003). The family of septins is highly
conserved across species as wide-
ranging as worms, flies, mice, and hu-
mans. In humans, more than 12 septin
genes have been isolated with numer-
ous splice variants, accounting for an
even greater variability. Functions of
these septins in mammals are quite
diverse and include roles in apoptosis,
exocytosis, cytokinesis, and micro-
tubule and actin function (reviewed in
Hall and Russell [2004]). Many of these
roles rely on septins to provide a scaf-
fold for the correct vesicle trafficking
or assembly of signaling complexes
(Kartmann and Roth, 2001).
Scaffold proteins such as spectrins,
caveolin, and flotillin have been previ-
ously shown to play important roles in
synaptic transmission by integrating
signaling pathways and regulating the
cycling of receptors (Pielage et al.,
2005). These modulatory effects of
scaffold molecules on signaling path-
ways such as ERK, JNK, and Akt might
occur at the caveolae (Smart et al.,
1999; Figure 1). These areas of spe-
cialized membrane, also known as
lipid rafts, are enriched in scaffolding
molecules. Alterations in scaffold pro-
teins have been previously observed
in AD, PD, and prion diseases (Fig-
ure 1). Moreover, alterations in neuro-
nal signaling in these disorders might
be related to the accumulation of mis-
folded molecules including Huntingtin
(Htt), Ab, PrP, and SYN.Neuron 53, FeAbnormalities in septin expression
or function in humans have been linked
to numerous diseases. Chromosomal
translocations resulting in the fusion
of MLL with septin 5, 6, 9, or 11 have
been linked with leukemia (Kreuziger
et al., 2007). Additionally, Sept9 has
been linked to sporadic ovarian and
breast cancer (Russell et al., 2000). In
neuronal diseases, septins 1, 2, and 4
have been found localized at the site
of neurofibrillary Tau tangles in AD,
although the significance of this has
not been determined (Hall and Russell,
2004). In addition, polymorphisms in
Sept3 have been associated with AD
(Takehashi et al., 2004). Furthermore,
Sept5 has been reported to bind Par-
kin and has been shown to accumulate
in patients with juvenile parkinsonism.
Although numerous septin knockout
mice have been generated, only the
Sept4 knockout appears to exhibit
neuronal abnormalities.
Ihara et al. examined the role of
Sept4 in the presynaptic termini scaf-
fold as well as in the pathogenesis of
PD. Their study describes three signif-
icant findings: (1) in cases with PD,
Sept4 colocalizes with SYN and is
downregulated in the putamen of these
patients; (2) loss of Sept4 in knockout
mice resulted in decreased dopamine
release, an effect which was recovered
when these mice were crossed with
a Sept4 transgenic mouse; and (3)
Sept4 binds SYN, preventing both its
phosphorylation and oligomerization.bruary 15, 2007 ª2007 Elsevier Inc. 469
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mine transporter (DAT), stx, snap25,
and SYN, all proteins that are involved
in the dopaminergic system. Addition-
ally, crosses of the Setp4 knockout
mouse with the SYN transgenic A53T
mouse, a model of PD, exacerbated
the neuronal loss and behavioral phe-
notype. Thus, Sept4 appears to play
an innate role in the dopaminergic
pathway, possibly by acting as a scaf-
fold for the assembly and release of
vesicles and interactions with other
synaptic molecules (Figure 1).
These findings naturally lead us to
ask the following question: can Sept4
be utilized as a therapy for PD? Ihara
et al. (2007) described a reduction in
Figure 1. Proposed Mechanisms
through Which Scaffold Molecules
Such as Septin4 Might Modulate
Dopaminergic Vesicle Release and SYN
Location and Phosphorylation in the
Caveolae
Interactions between septin4 and syntaxin,
SNAP25, and other synaptic proteins at the
caveolae might modulate vesicle release. In
addition, interactions with SYN might regulate
signaling pathways integrated at the caveolar
site that are important for neuronal survival.
Reduced concentrations of Sept4 might result
in abnormal interactions between SYN and
signaling molecules and aberrant phosphory-
lation of SYN leading to oligomerization.470 Neuron 53, February 15, 2007 ª2007the expression of Sept4 in the putamen
of patients with PD. This, along with the
data showing a relationship between
the presence of Sept4 and prevention
of oligomerization of SYN, supports
the potential value of Sept4 as a thera-
peutic target. In this context, it may be
possible to treat some forms of PD by
upregulating the expression of Sept4
at the synapses. Ihara et al. (2007) de-
scribe that overexpression of Sept4 is
potentially toxic in the mouse; how-
ever, this model was a transgenic ani-
mal containing Sept4 driven from the
prion promoter. The mouse exhibited
early death and loss of fertility, indicat-
ing that expression of Sept4 above en-
dogenous levels may not be beneficial.
It would have been interesting to deter-
mine if crossing the Sept4 transgenic
with the SYN transgenic would have
had an effect on dopaminergic neuro-
nal survival. Moreover, it remains to
be clarified why Sept4 expression is
reduced in PD.
Another potential therapeutic ap-
proach with Sept4 may be localized
delivery of the gene to the site of neu-
ronal cell death. Stereotactic delivery
of either a lentiviral or AAV vector ex-
pressing Sept4 from a dopaminergic
neuronal-specific promoter might pro-
vide the beneficial effects of prevent-
ing SYN aggregation without the detri-
mental effects of early death observed
in the transgenic mouse. We have pre-
viously shown that a similar approach
using lentiviral vectors expressing
other chaperone molecules might be
effective at suppressing SYN aggrega-
tion and toxicity (Hashimoto et al.,
2004; Klucken et al., 2004). In sum-
mary, this study provides new evi-
dence for the role of scaffold mole-Elsevier Inc.cules such as septins in synaptic
transmission and neurodegenerative
diseases and uncovered a new path-
way for better understanding the path-
ogenesis of PD and developing new
treatments.
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